Poseida Therapeutics

Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.

Launch date

2015

Employees

Market cap

Enterprise valuation

€131m (Public information from Sep 2024)

San Diego California (HQ)

http://poseida.com

https://twitter.com/poseidathera https://www.linkedin.com/company/poseida-therapeutics-inc-

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	-	<1m	130m	64.7m	86.6m	43.3m	22.0m
% growth	-	-	417635 %	(50 %)	34 %	(50 %)	(49 %)
EBITDA	(<1m)	(<1m)	(57.1m)	(109m)	-	-	-
% EBITDA margin	-	(389 %)	(44 %)	(169 %)	-	-	-
Profit	(<1m)	(<1m)	(64.0m)	(123m)	(146m)	(235m)	(288m)
% profit margin	-	(400 %)	(49 %)	(191 %)	(169 %)	(542 %)	(1311 %)
EV / revenue	-	13627.6x	3.5x	5.0x	3.2x	6.4x	12.6x
EV / EBITDA	-5371.1x	-3500.4x	-8.0x	-3.0x	-	-	-
R&D budget	<1m	<1m	153m	157m	-	-	-
R&D % of revenue	-	438 %	117 %	242 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Rapha Capital Management	N/A	-
Dec 2015	Malin Corporation	$23.0m	Series A
Aug 2017	N/A	$11.2m	Early VC
Oct 2017	California Institute for Regenerative Medicine	$19.8m	Grant
Apr 2018	Vivo Capital Longitude Capital	$30.5m	Series B
Apr 2019	Aisling Capital Vivo Capital Novartis Longitude Capital Perceptive Advisors Malin Corporation Amblyotech Boxer Capital	$142m	Series C
Jun 2020	Fidelity Investments Adage Capital Schonfeld Strategic Advisors	$110m Valuation: $710m -9.4x EV/LTM EBITDA	Series D
Jul 2020	N/A	N/A	IPO
Aug 2022*	N/A	N/A	Post IPO Equity
Aug 2023*	Astellas Pharma	$50.0m	Post IPO Equity
Total Funding		€306m

Tech stackLearn more about the technologies and tools that this company uses.